From Nuclear Winter to Renewal: Biotech Investing for 2026
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Maha Katabi, general partner at Sofinnova Investments and Andrew Lam, managing director, head of Biotech Private Equity at Ally Bridge Group, about how M &A dynamics, dealmaking and global partnerships are reshaping portfolio valuations and paths to growth in 2026.
Host
Jennifer Smith-Parker, Director of Insights, BioSpace
Guests
Maha Katabi, General Partner, Sofinnova Investments
Andrew Lam, Managing Director, Head of Biotech Private Equity, Ally Bridge Group (ABG)
Disclaimer: The views expressed in this discussion by guests…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.